

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate

March 17, 2026

### **Therapeutic category**

Anti-virus agents

### **Non-proprietary name**

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate

### **Safety measure**

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.  
 This English version is intended to be a reference material to provide convenience for users.  
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision												
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Carbamazepine, phenobarbital, phenytoin, fosphenytoin, rifampicin, food containing St. John's Wort, dihydroergotamine mesilate, ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, ergometrine maleate, methylergometrine maleate, asunaprevir, simvastatin, pimozide, sildenafil citrate (Revatio), vardenafil hydrochloride hydrate, tadalafil (Adcirca), blonanserin, azelnidipine, rivaroxaban, triazolam, midazolam, lomitapide mesilate, telaprevir</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <table border="1" data-bbox="239 1114 1090 1398"> <thead> <tr> <th data-bbox="239 1114 582 1214">Drugs</th> <th data-bbox="584 1114 869 1214">Signs, symptoms, and treatment</th> <th data-bbox="871 1114 1090 1214">Mechanism/risk factors</th> </tr> </thead> <tbody> <tr> <td data-bbox="239 1216 582 1398">Carbamazepine Phenobarbital Phenytoin Fosphenytoin</td> <td data-bbox="584 1216 869 1398">The blood concentration of elvitegravir and cobicistat may</td> <td data-bbox="871 1216 1090 1398">It is considered that these drugs induce CYP3A and P-gp.</td> </tr> </tbody> </table>	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Carbamazepine Phenobarbital Phenytoin Fosphenytoin	The blood concentration of elvitegravir and cobicistat may	It is considered that these drugs induce CYP3A and P-gp.	<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Carbamazepine, phenobarbital, phenytoin, fosphenytoin, rifampicin, <u>apalutamide</u>, food containing St. John's Wort, <u>enzalutamide</u>, dihydroergotamine mesilate, ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, ergometrine maleate, methylergometrine maleate, asunaprevir, simvastatin, pimozide, sildenafil citrate (Revatio), vardenafil hydrochloride hydrate, tadalafil (Adcirca), blonanserin, azelnidipine, rivaroxaban, triazolam, midazolam, lomitapide mesilate, <u>eplerenone</u>, telaprevir</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <table border="1" data-bbox="1133 1066 1984 1398"> <thead> <tr> <th data-bbox="1133 1066 1476 1161">Drugs</th> <th data-bbox="1478 1066 1762 1161">Signs, symptoms, and treatment</th> <th data-bbox="1765 1066 1984 1161">Mechanism/risk factors</th> </tr> </thead> <tbody> <tr> <td data-bbox="1133 1163 1476 1398">Carbamazepine Phenobarbital Phenytoin Fosphenytoin Rifampicin</td> <td data-bbox="1478 1163 1762 1398">The blood concentration of elvitegravir and cobicistat may significantly</td> <td data-bbox="1765 1163 1984 1398">It is considered that these drugs induce CYP3A and P-gp.</td> </tr> </tbody> </table>	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Carbamazepine Phenobarbital Phenytoin Fosphenytoin Rifampicin	The blood concentration of elvitegravir and cobicistat may significantly	It is considered that these drugs induce CYP3A and P-gp.
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors											
Carbamazepine Phenobarbital Phenytoin Fosphenytoin	The blood concentration of elvitegravir and cobicistat may	It is considered that these drugs induce CYP3A and P-gp.											
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors											
Carbamazepine Phenobarbital Phenytoin Fosphenytoin Rifampicin	The blood concentration of elvitegravir and cobicistat may significantly	It is considered that these drugs induce CYP3A and P-gp.											

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Rifampicin Food containing St. John's Wort	significantly decrease. The blood concentration of tenofovir alafenamide may also decrease.		<u>Apalutamide</u> Food containing St. John's Wort	decrease. The blood concentration of tenofovir alafenamide may also decrease.	
(N/A)			Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
			<u>Enzalutamide</u>	<u>The blood concentration of elvitegravir and cobicistat may significantly decrease.</u>	<u>It is considered that enzalutamide induces CYP3A.</u>
			<u>Eplerenone</u>	<u>The blood concentration of eplerenone may increase, and an increase in serum potassium levels may be induced.</u>	<u>It is considered that cobicistat inhibits CYP3A.</u>

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.